Drug Search Results
More Filters [+]


Alternative Names: bnt-212, bnt 212, bnt212
Latest Update: 2021-06-04
Latest Update Note: Clinical Trial Update

Product Description

BNT212 is a CAR-T cell therapy directed against the tumor antigen Claudin 18.2 (CLDN18.2), which is expressed in numerous epithelial solid tumors, including gastric, pancreatic, esophageal, ovarian and lung tumors. (Sourced from: https://www.biontech.com/int/en/home/pipeline-and-products/pipeline.html#bnt212-pancreatic-cancer)

Mechanisms of Action: CAR-T,CLDN18.2

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BioNTech
Company Location: MAINZ 2M 55131
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BNT-212

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified



Trial Status


Primary Completion Date

Probability of Success

Recent News Events